Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00319293

Enrollment

Registered

2006-04-27

Start date

Unknown

Completion date

Unknown

Last updated

2006-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Brief summary

Insulin resistance is an important feature of the polycystic ovary syndrome,and patiens are successfully treated with the insulin sensitizing agent metformin. The insulin resistance of lean patients with the syndrome is debated. In this study, we will study the change in insulin resistance, metabolic and hormonal factors after 3 months of metformin treatment in lean PCOS women.

Interventions

DRUGMetformin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 35 Years

Healthy volunteers

Inclusion criteria

* PCOS (Rotterdam criteria) * BMI \< 27 * No medication for 3 months

Exclusion criteria

* Pregnancy * Lactation * Other endocrinologic disease

Design outcomes

Primary

Measure	Time frame
Insulin resistance	—
Hormonal factors	—
Metabolic factors	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026